Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of HCC.

Lauriane Blukacz Sandro NuciforoGeoffrey FucileFredrik Trulsson Urs DuthalerStefan WielandMarkus H Heim

Published in: Hepatology communications (2024)

The inhibitory effects of doxorubicin treatment and hypoxia on HCCO proliferation are variable, suggesting an important role of tumor-cell intrinsic properties in doxorubicin resistance. ABCB1 is a determinant of doxorubicin response in HCCOs. Combination treatment of doxorubicin and ABCB1 inhibition may increase the response rate to transarterial chemoembolization.

Keyphrases

drug delivery
cancer therapy
signaling pathway
stem cells
endothelial cells
cell therapy
combination therapy
radiofrequency ablation